[Skip to Navigation]
Comment & Response
September 2018

Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype

Author Affiliations
  • 1Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Montreal Heart Institute, Université de Montréal Beaulieu-Saucier, Montreal, Quebec, Canada
  • 3Montreal Heart Institute Coordinating Center, Universite de Montréal, Montreal, Quebec, Canada
JAMA Cardiol. 2018;3(9):897. doi:10.1001/jamacardio.2018.2379

To the Editor Nissen et al1 conducted a nested case-control study from a subgroup of the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial “to determine whether the association between the SNP [single-nucleotide polymorphism] in the ADCY9 gene and a reduction in major adverse cardiovascular events could be replicated for another cholesterol ester transfer protein inhibitor, evacetrapib, in patients with high-risk vascular disease.” The clear objective of presenting the rs1967309 SNP of 717 345 genotyped SNPs was to replicate the findings of the post hoc pharmacogenetic analysis from the dal-OUTCOMES trial, a placebo-controlled trial conducted with dalcetrapib.2

Add or change institution